6-MBPB

6-MBPB, also known as 6-(2-methylaminobutyl)benzofuran (6-MABB), is a monoamine releasing agent (MRA) and entactogen-like drug of the amphetamine, phenylisobutylamine, and benzofuran families.^{[1][2][3][4][5]} It is a positional isomer of 5-MBPB (5-MABB).^{[1][2][3][4][5]}

6-MBPB

Clinical data
Other names	6-MABB; 6-(2-Methylaminobutyl)benzofuran
Drug class	Serotonin–norepinephrine–dopamine releasing agent; Entactogen
Identifiers
IUPAC name 1-(1-benzofuran-6-yl)-N-methylbutan-2-amine
PubChem CID	163757284
ChEMBL	ChEMBL5404902
Chemical and physical data
Formula	C13H17NO
Molar mass	203.285 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC(CC1=CC2=C(C=C1)C=CO2)NC
InChI InChI=1S/C13H17NO/c1-3-12(14-2)8-10-4-5-11-6-7-15-13(11)9-10/h4-7,9,12,14H,3,8H2,1-2H3 Key:LVDZDORQOMAGGH-UHFFFAOYSA-N

The drug appears to act as a serotonin–norepinephrine–dopamine releasing agent (SNDRA).^[1][2] The EC₅₀Tooltip half-maximal effective concentration values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of 6-MBPB.^[2] In the case of (S)-6-MBPB, they were 54 nM for serotonin, 77 nM for norepinephrine, and 41 nM for dopamine, whereas for (R)-6-MBPB, they were 172 nM for serotonin, 227 nM for norepinephrine, and inactive for dopamine.^[2] Hence, (S)-6-MBPB is an SNDRA, whereas (R)-MBPB is a serotonin–norepinephrine releasing agent (SNRA).^[2] The enantiomers showed a mixed profile of acting as full versus partial releasers.^[2] 6-MBPB partially substituted for MDMA in animal drug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects.^[1][2][4]

Along with 5-MBPB, 6-MBPB was patented by Matthew Baggott and Tactogen in 2021.^[5] It was first described in the scientific literature by 2022.^[3][4] 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine.^[1][2]